MedPath

Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine

Not Applicable
Active, not recruiting
Conditions
Hand and Foot Skin Reaction
Capecitabine
Hand and Foot Syndrome
Interventions
Dietary Supplement: Extra Virgin Olive Oil
Dietary Supplement: Olive Oil
Dietary Supplement: Placebo
Registration Number
NCT06188000
Lead Sponsor
Universitas Sriwijaya
Brief Summary

The study was aimed to evaluate the efficacy of extra virgin olive oil (EVOO) supplementation compared to placebo to prevent HFS by observing changes in serum COX 2, malondialdehyde (MDA), and TNF α levels in breast cancer and colorectal cancer patients undergoing capecitabine chemotherapy. Current study was designed as a single-center prospective randomized clinical trial. The patients were Stage III or Stage IV colorectal and breast cancer patients receiving capecitabine-based chemotherapy who enrolled in the trial voluntarily. All patients were divided randomly into three groups treated with EVOO, olive oil, or placebo. The incidence of hand foot syndrome was documented. The serum COX 2, malondialdehyde (MDA), and TNF α levels before and after chemotherapy was documented.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Patients pathologically and clinically diagnosed with III or IV stadium of breast cancer or colorectal cancer.
  • fully recovered after curative resection within 8 weeks
  • receive adjuvant capecitabine based chemotherapy
Exclusion Criteria
  • did not meet the eligibility criteria for chemotherapy
  • had previous allergy with capecitabine or olive oil

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Extra Virgin Olive OilExtra Virgin Olive OilThe patients was given a capsule contained extra virgin olive oil 15 milliliters twice a day.
Olive OilOlive OilThe patients was given a capsule contained olive oil 15 milliliters twice a day.
PlaceboPlaceboThe patients was given an empty capsule twice a day.
Primary Outcome Measures
NameTimeMethod
Serum COX-2 Concentration3 cycle of chemotherapy (63 days)

Serum COX-2 Concentration

Hand Foot Syndrome3 cycle of chemotherapy (63 days)

Patients was documented for hand and foot syndrome using WHO criteria. There were 4 grade assessed by patient symptoms of tingling or burning or painful sensation, palmar or plantar erythema or desquamation, and/or ulceration.

Serum Tumor Necrosis Factor Alpha Concentration3 cycle of chemotherapy (63 days)

Serum Tumor Necrosis Factor Alpha Concentration

Serum malondialdehyde concentration3 cycle of chemotherapy (63 days)

Serum malondialdehyde ceoncentration

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Rumah Sakit Mohammad Hoesin

🇮🇩

Palembang, South Sumatera, Indonesia

© Copyright 2025. All Rights Reserved by MedPath